| Report ID | 283039 |
| Drug Identification Number | 02484218 |
| Brand name | VYZULTA |
| Common or Proper name | Vyvulta |
| Company Name | BAUSCH & LOMB INC |
| Market Status | MARKETED |
| Active Ingredient(s) | LATANOPROSTENE BUNOD |
| Strength(s) | 0.024% |
| Dosage form(s) | SOLUTION |
| Route of administration | OPHTHALMIC OPHTHALMIC |
| Packaging size | 1 |
| Anatomical Therapeutical Chemical (ATC) code | S01EE |
| Anatomical Therapeutical Chemical (ATC) description | |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | 2026-04-21 |
| Actual start date | |
| Estimated end date | 2026-05-16 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-04-18 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1400 N GOODMAN STREET ROCHESTER, NEW YORK UNITED STATES 14609 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-04-16 | French | Compare |
| v1 | 2026-04-16 | English | Compare |
Showing 1 to 2 of 2